瑞聲科技(02018.HK)斥4.5億人幣收購東陽精密機器全部股權
瑞聲科技(02018.HK)公布,與賣方株式會社東陽理化學研究所訂立股權轉讓協議,計劃以代價4.5億元人民幣購買東陽精密機器(昆山)有限公司的100%股權,將以內部資源支付。
東陽精密機器主要業務為設計、開發及製造資訊科技產品所用的金屬框架材料,包括製造平板電腦、可穿戴設備及筆記本電腦產品的金屬框架、底殼及零部件,其工廠設於中國江蘇省昆山市,面積約為5.2萬平方米。
公司表示,該公司專門為歐美客戶設計、開發並製造平板電腦、可穿戴設備及筆記本電腦的金屬框架、底殼及零部件材料,預期收購有助對外發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.